LJP1485

LJP1485 is an investigational regenerative immunophilin ligand being developed to promote tissue regeneration and scar remodeling following acute injury. Preclinical animal models described by La Jolla Pharmaceutical indicate that LJP1485 can induce stem cell‑like cells at sites of surgical wounds, lung injury, or myocardial infarction, which then differentiate into site‑specific, fully functional tissue under local cues, leading to accelerated healing with more normal tissue architecture and reduced fibrosis.[1][4][9] The compound originated from GliaMed’s regenerative immunophilin ligand platform, for which La Jolla Pharmaceutical licensed rights, and has been advanced primarily in preclinical development with an initial focus on post‑surgical scar remodeling and fibrotic injury.[1][4][9]